AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10354255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse standing orders with compliance reminders and patient and clinician reminders
Number of subjects: 3502
Study 10354255 — intervention group
Group type: COMPARATOR
Intervention: Patient and clinician reminders alone
Number of subjects: 3502
Study 8573004 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly dialysis (Kr = 0)
Number of subjects: 2
Study 8573004 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly dialysis (nonzero Kr)
Number of subjects: 2
Study 2197208 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated group (n=51)
Number of subjects: 103
Study 2197208 — intervention group
Group type: COMPARATOR
Intervention: Nonoperated group (n=52)
Number of subjects: 103
Study 7000233 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (gastric surgery)
Number of subjects: 118
Study 7000233 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 118
Study 31466854 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg with carboplatin and etoposide
Number of subjects: 42
Study 31466854 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin and etoposide
Number of subjects: 42
Study 29550804 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB transfusion (n = 5), administered once within 5 days of birth (mean 3.2 ± 1.9 days)
Number of subjects: 20
Study 29550804 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic RBC transfusions (n = 15), administered 7.8 ± 3.9 days after birth
Number of subjects: 20
Study 29550804 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB transfusion (n = 5)
Number of subjects: 20
Study 25886645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) containing anti-JEV neutralizing antibody (ImmunoRel, 400mg/kg/day for 5 days)
Number of subjects: 22
Study 25886645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24156728 — intervention group
Group type: EXPERIMENTAL
Intervention: One titanium elastic nail (TEN)
Number of subjects: 67
Study 24156728 — intervention group
Group type: EXPERIMENTAL
Intervention: Two titanium elastic nails (TENs)
Number of subjects: 67
Study 24156728 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study 21257061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-salts of fatty acids (CaFA)
Number of subjects: 0
Study 21257061 — intervention group
Group type: COMPARATOR
Intervention: Control diet (2.9% DM as long-chain fatty acids)
Number of subjects: 0
Study 21257061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-supplemented diets (CaFA, SFA, TAG)
Number of subjects: 0
Study 21257061 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated free fatty acids (SFA)
Number of subjects: 0
Study 21257061 — intervention group
Group type: EXPERIMENTAL
Intervention: Triacylglyceride high in C16:0 fatty acids (TAG)
Number of subjects: 0
Study 19074516 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP >2.0 mg/L
Number of subjects: 4162
Study 19074516 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP >80 ng/L
Number of subjects: 4162
Study 19074516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hsCRP and BNP increased
Number of subjects: 4162
Study 19074516 — intervention group
Group type: COMPARATOR
Intervention: Intensive statin therapy
Number of subjects: 4162
Study 19074516 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP quartile Q4 vs Q1
Number of subjects: 4162
Study 19074516 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP quartile Q4 vs Q1
Number of subjects: 4162
Study 16324780 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 UI of lyophilized HAase (5 ml)
Number of subjects: 168
Study 14998735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-dose training (n = 16)
Number of subjects: 79
Study 14998735 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 79
Study 11391327 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter device
Number of subjects: 40
Study 9069614 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp cooling regimen (19 patients)
Number of subjects: 35
Study 9069614 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature regimen (16 patients)
Number of subjects: 35
Study 8275350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (SCT) 200 IU
Number of subjects: 12
Study 3553874 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine in elderly subjects (70% vaccinated)
Number of subjects: 691
Study 3553874 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine in younger subjects (50% vaccinated)
Number of subjects: 691
Study 3553874 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine in younger subjects
Number of subjects: 691
Study 3553874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing antibody levels in elderly subjects
Number of subjects: 691
Study 30919581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturations at time of discharge from stage‐I and stage‐II surgeries
Number of subjects: 328
Study 30919581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation measurements below 80%
Number of subjects: 328
Study 30919581 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in oxygen saturations over time
Number of subjects: 328
Study 28886758 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 80 micrograms/day
Number of subjects: 270
Study 28886758 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 160 micrograms/day
Number of subjects: 270
Study 28886758 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI 80 or 160 micrograms/day
Number of subjects: 270
Study 28886758 — intervention group
Group type: COMPARATOR
Intervention: Placebo BAI
Number of subjects: 270
Study 26712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with normal Body Mass Index (BMI)
Number of subjects: 816
Study 26712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents classified as overweight
Number of subjects: 816
Study 26712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents classified as obese
Number of subjects: 816
Study 26712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers classified as overweight or obese
Number of subjects: 816
Study 26712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers classified as overweight or obese
Number of subjects: 816
Study 26712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with adolescent overweight or obesity
Number of subjects: 816
Study 24267258 — intervention group
Group type: EXPERIMENTAL
Intervention: HTE-DLP (Computerized Decision Support System)
Number of subjects: 77
Study 24267258 — intervention group
Group type: EXPERIMENTAL
Intervention: High potency statins and combined therapy
Number of subjects: 77
Study 24267258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 77
Study 24267258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 77
Study 24267258 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician agreement and ease-of-use
Number of subjects: 77
Study 21773992 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 µg daily for 24 weeks
Number of subjects: 62
Study 21773992 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84)
Number of subjects: 62
Study 21773992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19435203 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed sorbent (microcellulose + polysorb) (6g), administered once a week, on average 20 days after operation.
Number of subjects: 30
Study 19435203 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned).
Number of subjects: 30
Study 16712652 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIT1 amino acid variants Gly102Ser and Ala442Gly
Number of subjects: 322
Study 16712652 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 bp duplication within CHIT1
Number of subjects: 322
Study 16712652 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 322
Study 16712652 — intervention group
Group type: COMPARATOR
Intervention: Adult controls
Number of subjects: 322
Study 14697069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric diet (milk formula supplemented with 5% to 7% glucose polymers and 3% to 5% medium chain triglycerides)
Number of subjects: 23
Study 14697069 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (milk formula only)
Number of subjects: 23
Study 14697069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 12195605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (Arixtra TM)
Number of subjects: 0
Study 12195605 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 9440758 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 mRNA levels less than or equal to 5.8 x 10(‐3)
Number of subjects: 38
Study 9440758 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 mRNA levels greater than 5.8 x 10(‐3)
Number of subjects: 38
Study 9440758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ERCC1 and TS mRNA levels below their medians
Number of subjects: 38
Study 9440758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ERCC1 and TS mRNA levels above their medians
Number of subjects: 38
Study 9440758 — intervention group
Group type: EXPERIMENTAL
Intervention: TS mRNA levels
Number of subjects: 38
Study 8270988 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: P 30 mg/m2 IV bolus followed by E 130 mg/m2 bolus
Number of subjects: 552
Study 8270988 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: E 130 mg/m2 bolus followed by P 30 mg/m2 bolus
Number of subjects: 552
Study 8270988 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C: E 130 mg/m2 by 24-hour infusion and P 30 mg/m2 bolus at the end of each 24-hour infusion of E
Number of subjects: 552
Study 8270988 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm D: E 130 mg/m2 by 24-hour infusion and P 45 mg/m2 by 24-hour infusion on day 2 and 3 only
Number of subjects: 552
Study 2572797 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tyrosine (9 g daily for 4 weeks)
Number of subjects: 10
Study 2572797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 239966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose practolol (1.5 mg/kg)
Number of subjects: 0
Study 239966 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose practolol (12 mg/kg)
Number of subjects: 0
Study 239966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29649916 — intervention group
Group type: EXPERIMENTAL
Intervention: Breezhaler®
Number of subjects: 100
Study 29649916 — intervention group
Group type: COMPARATOR
Intervention: Ellipta®
Number of subjects: 100
Study 28457097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hévíz mud applied directly to both hands (n=23)
Number of subjects: 47
Study 28457097 — intervention group
Group type: COMPARATOR
Intervention: Nylon gloves separating the skin from the mud (n=24)
Number of subjects: 47
Study 26048068 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 64
Study 26048068 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 64
Study 26048068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study 23504930 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hormone therapy (futamide plus a luteinizing hormone-releasing hormone agonist for 4 months)
Number of subjects: 1070
Study 22365398 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (Al‐OH) adjuvant
Number of subjects: 0
Study 22365398 — intervention group
Group type: COMPARATOR
Intervention: No aluminum hydroxide (placebo)
Number of subjects: 0
Study 19351542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular Botulinum Toxin Type A (IA-BoNT/A)
Number of subjects: 0
Study 19351542 — intervention group
Group type: COMPARATOR
Intervention: IA-BoNT/A
Number of subjects: 0
Study 16643222 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70
Study 16643222 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 70
Study 14566568 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingested 30 min before exercise (50 g)
Number of subjects: 6
Study 14566568 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingested during exercise (110 g or 160 g in fractionated doses)
Number of subjects: 6
Study 14566568 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingested both before and during exercise (50 g before and 110 g during)
Number of subjects: 6
Study 14566568 — intervention group
Group type: COMPARATOR
Intervention: Placebo or unlabelled glucose ingested during exercise
Number of subjects: 6
Study 11209991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity primary care-based intervention to prevent depression relapse, including education about depression, motivation-enhancing shared decision-making, and cognitive-behavioral strategies.
Number of subjects: 194
Study 8770969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (1 to 3 mg/m2/day)
Number of subjects: 70
Study 8770969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (5 to 6 mg/m2/day)
Number of subjects: 70
Study 8770969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (7 to 13 mg/m2/day)
Number of subjects: 70
Study 8770969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/m2/day)
Number of subjects: 70
Study 8770969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (any dose)
Number of subjects: 70
Study 8770969 — intervention group
Group type: COMPARATOR
Intervention: Control group (CsA/corticosteroid regimen)
Number of subjects: 70
Study 1612040 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone 65 mg in 90 ml of water
Number of subjects: 330
Study 1612040 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone 65 mg in 30 ml of water
Number of subjects: 330
Study 1612040 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone 195 mg in 90 ml of water
Number of subjects: 330
Study 1612040 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 330
Study 1612040 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone (any dosage)
Number of subjects: 330
Study 6374678 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol (1 to 2 mg per day)
Number of subjects: 120
Study 6374678 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 to 10 mg per day)
Number of subjects: 120
Study 30879470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) consisting of 10 therapy sessions over 3 months, followed by four maintenance sessions over 6 months.
Number of subjects: 475
Study 30879470 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 475
Study 28689852 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy for co-occurring opioid use disorder and anxiety disorders
Number of subjects: 0
Study 28689852 — intervention group
Group type: COMPARATOR
Intervention: Active comparison treatment targeting opioid use disorder alone
Number of subjects: 0
Study 25975527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure of defects after endoscopic resection
Number of subjects: 348
Study 25975527 — intervention group
Group type: COMPARATOR
Intervention: No closure of defects after endoscopic resection
Number of subjects: 348
Study 24127679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tristel Fuse (chlorine dioxide)
Number of subjects: 180
Study 24127679 — intervention group
Group type: COMPARATOR
Intervention: Cidex OPA (ortho-phthaldehyde)
Number of subjects: 180
Study 22687658 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching (contract-release technique)
Number of subjects: 45
Study 22687658 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 45
Study 22687658 — intervention group
Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 45
Study 22687658 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF vs Static
Number of subjects: 45
Study 19114907 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vital capacity maneuver (VCM)
Number of subjects: 50
Study 16772353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (10 pmol/kg.min) infusion for 180 min
Number of subjects: 0
Study 16772353 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 16772353 — intervention group
Group type: EXPERIMENTAL
Intervention: GH substitution in GH-deficient patients
Number of subjects: 0
Study 15352043 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-carotene (highest quartile)
Number of subjects: 834
Study 15352043 — intervention group
Group type: EXPERIMENTAL
Intervention: dietary intakes of alpha-carotene
Number of subjects: 834
Study 15352043 — intervention group
Group type: EXPERIMENTAL
Intervention: dietary intakes of vitamin A
Number of subjects: 834
Study 15352043 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (highest quartile)
Number of subjects: 834
Study 10694094 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific antiglycolipid antibodies in serum and circulating immune complexes
Number of subjects: 53
Study 10694094 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibody levels against glycolipid LOS
Number of subjects: 53
Study 10694094 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibody against LOS
Number of subjects: 53
Study 10694094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antigens tested in serum
Number of subjects: 53
Study 10694094 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of immune complexes and IgG antibodies against glycolipid antigens
Number of subjects: 53
Study 9333047 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 24
Study 9333047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed (high-fat meal)
Number of subjects: 24
Study 9333047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting with sucralfate
Number of subjects: 24
Study 1304698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansimef
Number of subjects: 567
Study 1304698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study 1304698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lariam
Number of subjects: 567
Study 1304698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar
Number of subjects: 567
Study 1304698 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 567
Study 1304698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 567
Study 4075722 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon cleansing
Number of subjects: 133
Study 3233058 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg.kg‐1 every 12 hours by IV route
Number of subjects: 21
Study 3233058 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 40 mg.kg‐1 every 12 hours by oral route
Number of subjects: 21
Study 29247809 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diclofenac (two doses of 75mg in the first 24h after diagnosis)
Number of subjects: 34
Study 29247809 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 34
Study 28111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 28111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 28111801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28111801 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg and 150 mg
Number of subjects: 0
Study 25687568 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus salivarius UCC118)
Number of subjects: 149
Study 25687568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 23791063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol patch
Number of subjects: 92
Study 23791063 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol sulfate
Number of subjects: 92
Study 21612452 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental green tea extract (40 mL, rinsed for 1 minute, three times a day for a week)
Number of subjects: 66
Study 21612452 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (40 mL, rinsed for 1 minute, three times a day for a week)
Number of subjects: 66
Study 18209254 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice moderate-intensity walking (55%-70% of maximum heart rate)
Number of subjects: 75
Study 18209254 — intervention group
Group type: COMPARATOR
Intervention: No practice
Number of subjects: 75
Study 16757422 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement in patients with recruitable myocardium (group 1)
Number of subjects: 27
Study 16757422 — intervention group
Group type: COMPARATOR
Intervention: Aortic valve replacement in patients without recruitable myocardium (group 2)
Number of subjects: 27
Study 16757422 — intervention group
Group type: COMPARATOR
Intervention: Comparison of functional capacity improvement between groups
Number of subjects: 27
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC7 (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d. for 7 days)
Number of subjects: 287
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC14 (clarithromycin 500 mg b.d. for 14 days)
Number of subjects: 287
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: OAM14 (metronidazole 500 mg b.d. for 14 days)
Number of subjects: 287
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-based treatment (clarithromycin-susceptible strains: OAC14, others: OAM14)
Number of subjects: 287
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-susceptible strains
Number of subjects: 287
Study 14535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 287